Loading insider details...
Beta
Latest Form 4 (Sep 1, 2026): Exercise/Conversion of 679 AVTX shares, $5.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Avalo Therapeutics, Inc. (AVTX) | Exercise/Conversion | 679 | $5.5K |
| Aug 19, 2026 | Avalo Therapeutics, Inc. (AVTX) | Exercise/Conversion | 1,000 | $12.7K |
| Aug 12, 2026 | Avalo Therapeutics, Inc. (AVTX) | Exercise/Conversion | 679 | $5.5K |
| Jul 29, 2026 | Avalo Therapeutics, Inc. (AVTX) | Exercise/Conversion | 1,000 | $12.7K |
| Jul 2, 2026 | Avalo Therapeutics, Inc. (AVTX) | Exercise/Conversion | 2,875 | $36.4K |
| Jun 25, 2026 | Avalo Therapeutics, Inc. (AVTX) | Exercise/Conversion | 1,450 | $11.7K |
| Jun 18, 2026 | Cullinan Therapeutics, Inc. (CGEM) | Grant/Award | 21,781 | n/a |
| Jun 12, 2026 | Avalo Therapeutics, Inc. (AVTX) | Tax Withholding | 1,084 | $14.2K |
| Jun 1, 2026 | Avalo Therapeutics, Inc. (AVTX) | Exercise/Conversion | 679 | $5.5K |
| May 26, 2026 | Avalo Therapeutics, Inc. (AVTX) | Grant/Award | 43,500 | n/a |